ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Trading Down 1.9 %

Shares of IBRX stock opened at $2.62 on Friday. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -2.85 and a beta of 0.86. ImmunityBio has a 12-month low of $2.61 and a 12-month high of $10.53. The stock’s 50-day moving average price is $4.49 and its 200-day moving average price is $4.73.

Institutional Investors Weigh In On ImmunityBio

A number of large investors have recently modified their holdings of the business. State Street Corp raised its position in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after buying an additional 790,408 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of ImmunityBio by 37.9% in the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock valued at $3,928,000 after buying an additional 170,742 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares in the last quarter. Private Advisor Group LLC raised its position in shares of ImmunityBio by 727.7% during the 2nd quarter. Private Advisor Group LLC now owns 86,907 shares of the company’s stock worth $549,000 after purchasing an additional 76,407 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of ImmunityBio during the second quarter valued at approximately $118,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.